132 related articles for article (PubMed ID: 8189604)
1. Immunotherapy with keyhole limpet hemocyanin: efficacy and safety in the MB-49 intravesical murine bladder tumor model.
Swerdlow RD; Ratliff TL; La Regina M; Ritchey JK; Ebert RF
J Urol; 1994 Jun; 151(6):1718-22. PubMed ID: 8189604
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of murine bladder cancer with keyhole limpet hemocyanin (KLH).
Lamm DL; DeHaven JI; Riggs DR; Ebert RF
J Urol; 1993 Mar; 149(3):648-52. PubMed ID: 8437283
[TBL] [Abstract][Full Text] [Related]
3. Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies.
Lamm DL; Dehaven JI; Riggs DR
Eur Urol; 2000; 37 Suppl 3():41-4. PubMed ID: 10828686
[TBL] [Abstract][Full Text] [Related]
4. Keyhole limpet haemocyanin in experimental bladder cancer: literature review and own results.
Linn JF; Black P; Derksen K; Rübben H; Thüroff JW
Eur Urol; 2000; 37 Suppl 3():34-40. PubMed ID: 10828685
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of local Bacillus Calmette-Guérin treatment in superficial bladder cancer relapsing under Keyhole-Limpet Hemocyanin immunotherapy.
Jurincic-Winkler C; Engelmann U; Beuth J; Klippel KF
Zentralbl Bakteriol; 1995 Oct; 282(4):409-15. PubMed ID: 9810664
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study.
Jurincic CD; Engelmann U; Gasch J; Klippel KF
J Urol; 1988 Apr; 139(4):723-6. PubMed ID: 3127600
[TBL] [Abstract][Full Text] [Related]
7. Antibody response to keyhole limpet hemocyanin (KLH) treatment in patients with superficial bladder carcinoma.
Jurincic-Winkler CD; von der Kammer H; Beuth J; Scheit KH; Klippel KF
Anticancer Res; 1996; 16(4A):2105-10. PubMed ID: 8712751
[TBL] [Abstract][Full Text] [Related]
8. Superiority of intravesical immunotherapy with Corynebacterium parvum and Allium sativum in control of murine bladder cancer.
Marsh CL; Torrey RR; Woolley JL; Barker GR; Lau BH
J Urol; 1987 Feb; 137(2):359-62. PubMed ID: 3806842
[TBL] [Abstract][Full Text] [Related]
9. Keyhole limpet hemocyanin for carcinoma in situ of the bladder: a long-term follow-up study.
Jurincic-Winkler CD; Metz KA; Beuth J; Klippel KF
Eur Urol; 2000; 37 Suppl 3():45-9. PubMed ID: 10828687
[TBL] [Abstract][Full Text] [Related]
10. Effect of keyhole limpet hemocyanin (KLH) and bacillus Calmette-Guérin (BCG) instillation on carcinoma in situ of the urinary bladder.
Jurincic-Winkler C; Metz KA; Beuth J; Sippel J; Klippel KF
Anticancer Res; 1995; 15(6B):2771-6. PubMed ID: 8669862
[TBL] [Abstract][Full Text] [Related]
11. Keyhole limpet hemocyanin immunotherapy of murine bladder cancer.
Lamm DL; DeHaven JI; Riggs DR; Delgra C; Burrell R
Urol Res; 1993 Jan; 21(1):33-7. PubMed ID: 8456536
[TBL] [Abstract][Full Text] [Related]
12. Urinary interleukin-1 alpha levels are increased by intravesical instillation with keyhole limpet hemocyanin in patients with superficial transitional cell carcinoma of the bladder.
Jurincic-Winkler CD; Gallati H; Alvarez-Mon M; Sippel J; Carballido J; Klippel KF
Eur Urol; 1995; 28(4):334-9. PubMed ID: 8575503
[TBL] [Abstract][Full Text] [Related]
13. Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial.
Lammers RJ; Witjes WP; Janzing-Pastors MH; Caris CT; Witjes JA
J Clin Oncol; 2012 Jun; 30(18):2273-9. PubMed ID: 22585689
[TBL] [Abstract][Full Text] [Related]
14. In vitro anticancer effects of a novel immunostimulant: keyhole limpet hemocyanin.
Riggs DR; Jackson B; Vona-Davis L; McFadden D
J Surg Res; 2002 Dec; 108(2):279-84. PubMed ID: 12505053
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapeutic effect of Concholepas hemocyanin in the murine bladder cancer model: evidence for conserved antitumor properties among hemocyanins.
Moltedo B; Faunes F; Haussmann D; De Ioannes P; De Ioannes AE; Puente J; Becker MI
J Urol; 2006 Dec; 176(6 Pt 1):2690-5. PubMed ID: 17085197
[TBL] [Abstract][Full Text] [Related]
16. Recurrent superficial transitional cell carcinoma of the bladder: adjuvant topical chemotherapy versus immunotherapy. A prospective randomized trial.
Flamm J; Bucher A; Höltl W; Albrecht W
J Urol; 1990 Aug; 144(2 Pt 1):260-3. PubMed ID: 2197428
[TBL] [Abstract][Full Text] [Related]
17. [Topical immunotherapy (KLH) vs. chemotherapy (Ethoglucid) in prevention of recurrence of superficial bladder cancer. A prospective randomized study].
Flamm J; Donner G; Bucher A; Höltl W; Albrecht W; Havelec L
Urologe A; 1994 Mar; 33(2):138-43. PubMed ID: 8178408
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapeutic Potential of Mollusk Hemocyanins in Combination with Human Vaccine Adjuvants in Murine Models of Oral Cancer.
Mora Román JJ; Del Campo M; Villar J; Paolini F; Curzio G; Venuti A; Jara L; Ferreira J; Murgas P; Lladser A; Manubens A; Becker MI
J Immunol Res; 2019; 2019():7076942. PubMed ID: 30847353
[TBL] [Abstract][Full Text] [Related]
19. Keyhole-limpet haemocyanin (KLH) immunotherapy of murine transitional cell carcinoma.
Walsh WG; Tomashefsky P; Olsson CA; deVere White R
Urol Res; 1983; 11(6):263-5. PubMed ID: 6659223
[TBL] [Abstract][Full Text] [Related]
20. Immunohistological findings in patients with superficial bladder carcinoma after intravesical instillation of keyhole limpet haemocyanin.
Jurincic-Winkler C; Metz KA; Beuth J; Engelmann U; Klippel KF
Br J Urol; 1995 Dec; 76(6):702-7. PubMed ID: 8535712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]